Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 4, 2022Campaign Provides Educational Resources on Liver Cancer and Encourages People to Make Some Daily Adjustments to Help Support Liver Health NUTLEY, N.J., Aug. 4, 2022 /PRNewswire/ -- Baseball legend...
Aug 3, 2022RAHWAY, N.J. and NUTLEY, N.J., August 3, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Phase 3 LEAP-002 trial investigating...
Jun 5, 2022Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202)...
- May 27, 2022
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai's Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients...
Mar 30, 2022Spot Her Aims to Educate People About the Signs and Risk Factors of Endometrial Cancer, One of the Most Common Yet Under-Recognized Women's Cancers Actor Leads Spot Her Virtual Walk to Increase...
Jan 20, 2022KENILWORTH, N.J., and NUTLEY, N.J., January 20, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the publication of results from the Phase 3...
Jan 14, 2022Highlights include the primary analysis from the Phase 2 TACTICS-L study evaluating LENVIMA® (lenvatinib) in combination with TACE in unresectable hepatocellular carcinomaEisai announced today the presentation of six abstracts across various gastrointestinal cancers during the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium...
-
Dec 7, 2021
Eisai Inc. and METAvivor today announced the launch of fearLESS, a new initiative of the #ThisIsMBC campaign. FearLESS showcases content of a diverse group of 10 participants, who have a...
Sep 13, 2021Subgroup analyses from registrational Phase 3 KEYNOTE-775/Study 309 and CLEAR/KEYNOTE-581 trials provide additional data on KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib)Eisai Inc. announced today the presentation of 13 abstracts across multiple types of cancer from its oncology portfolio during the upcoming European Society for Medical Oncology (ESMO) Congress...
Aug 11, 2021KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCCKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Aug. 11, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...